Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxyethylcellulose 0.19%
- Development stage
- Unknown
- Lead developer
- Sheba Medical Center
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Hydroxyethylcellulose 0.19% is a cellulose-derived polymer that functions as a viscosity-increasing agent and an inert vehicle in ophthalmic preparations. In clinical research conducted by Sheba Medical Center, this specific concentration is utilized as a placebo control in a randomized, double-blind study. The trial evaluates the necessity and efficacy of topical anti-inflammatory treatments, specifically nepafenac 0.1% and dexamethasone 0.1%, in reducing inflammation and pain following laser peripheral iridotomy (LPI) in patients with primary angle-closure glaucoma. As a placebo, hydroxyethylcellulose 0.19% lacks active pharmacological properties or a specific biological target, serving primarily to maintain the integrity of the study's blinding process.
- Other names
- hydroxyethylcelluloseHEC
Beyond the preview
Go deeper on hydroxyethylcellulose 0.19%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxyethylcellulose 0.19%.